Clareo Health | Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients aged 18 or greater
Patients with carcinoid tumors and symptoms (diarrhea and flushing) that are not adequately controlled by somatostatin analogues.
Female patients of child bearing potential must have a negative pregnancy test at baseline.
Patients for whom written informed consent to participate in the study has been obtained.
You may not be if
Patients receiving radiolabeled somatostatin analogue therapy within the 3 months or any cytotoxic chemotherapy or interferon therapy within the 4 weeks prior to randomization
Diabetic patients on anti-diabetic medications whose fasting blood glucose is poorly controlled as indicated by HBA1C \> 8%
Patients with symptomatic cholelithiasis
Patient with malabsorption syndrome, short bowel or cholegenic diarrhea not controlled by specific therapeutic means.
